×
About 9,550 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  4,653 results

Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patien...
https://doi.org/10.1016/j.jocn.2020.06.023
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia; Fan X, Xing C et. al.

Oct 19th, 2020 - Muscle weakness related to myasthenia gravis (MG) limits the daily functioning of patients. MG patients often experience subjective symptoms including psychiatric disorders, fatigue, and reduction in self-efficacy. All of which ultimately influenc...

Identifying jitter outliers in single fiber electromyography: comparison of four methods.
https://doi.org/10.1002/mus.27093
Muscle & Nerve; Anagnostou E, Dimopoulou P et. al.

Oct 17th, 2020 - Little is known about how different outlier estimation methods affect cut-off limits for outliers in single fiber electromyography. We compared in a prospective fashion the established 18th -jitter value (18th jv) method to three, whole-distributi...

Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
https://doi.org/10.1016/j.jneuroim.2020.577424
Journal of Neuroimmunology; Uzawa A, Ozawa Y et. al.

Oct 17th, 2020 - Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. The neuromuscular junction damage associated with MG is caused by anti-acetylcholine receptor (AChR) antibody and complements. Recently, eculizumab (an anti-...

The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545457
Mediators of Inflammation; Xu L, Li Z et. al.

Oct 16th, 2020 - This study is aimed at exploring the expression pattern and methylation level of G0S2 in the peripheral blood mononuclear cells (PBMCs) of myasthenia gravis (MG) patients with positive acetylcholine receptor (AChR) autoantibodies and revealing the...

A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth horm...
https://doi.org/10.1177/0300060520961684
The Journal of International Medical Research; Zhou W, Lin H et. al.

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

see more →

Guidelines  9 results

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 9th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jun 30th, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

Guidelines for treatment of autoimmune neuromuscular transmission disorders.
https://doi.org/10.1111/j.1468-1331.2010.03019.x
European Journal of Neurology; Skeie GO, Apostolski S et. al.

Apr 20th, 2010 - Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). To prepare consensus guideli...

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological ...
https://doi.org/10.1111/j.1468-1331.2008.02246.x
European Journal of Neurology; Elovaara I, Apostolski S et. al.

Sep 17th, 2008 - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, ...

SOLIRIS® (ECULIZUMAB)
https://alexion.com/Products/Soliris

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  4,737 results

Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patien...
https://doi.org/10.1016/j.jocn.2020.06.023
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia; Fan X, Xing C et. al.

Oct 19th, 2020 - Muscle weakness related to myasthenia gravis (MG) limits the daily functioning of patients. MG patients often experience subjective symptoms including psychiatric disorders, fatigue, and reduction in self-efficacy. All of which ultimately influenc...

Identifying jitter outliers in single fiber electromyography: comparison of four methods.
https://doi.org/10.1002/mus.27093
Muscle & Nerve; Anagnostou E, Dimopoulou P et. al.

Oct 17th, 2020 - Little is known about how different outlier estimation methods affect cut-off limits for outliers in single fiber electromyography. We compared in a prospective fashion the established 18th -jitter value (18th jv) method to three, whole-distributi...

Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
https://doi.org/10.1016/j.jneuroim.2020.577424
Journal of Neuroimmunology; Uzawa A, Ozawa Y et. al.

Oct 17th, 2020 - Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. The neuromuscular junction damage associated with MG is caused by anti-acetylcholine receptor (AChR) antibody and complements. Recently, eculizumab (an anti-...

The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545457
Mediators of Inflammation; Xu L, Li Z et. al.

Oct 16th, 2020 - This study is aimed at exploring the expression pattern and methylation level of G0S2 in the peripheral blood mononuclear cells (PBMCs) of myasthenia gravis (MG) patients with positive acetylcholine receptor (AChR) autoantibodies and revealing the...

A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth horm...
https://doi.org/10.1177/0300060520961684
The Journal of International Medical Research; Zhou W, Lin H et. al.

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

see more →

News  75 results

Zilucoplan improved efficacy outcomes in myasthenia gravis
https://www.mdedge.com/jcomjournal/article/217505/rare-diseases/zilucoplan-improved-efficacy-outcomes-myasthenia-gravis?channel=39313
Andrew D. Bowser

Feb 19th, 2020 - The complement C5 inhibitor zilucoplan significantly improved muscle weakness and daily functioning in patients with moderate to severe generalized myasthenia gravis (gMG), according to investigators who conducted a phase 2, randomized, placebo-co.

AChR autoantibody subtype testing may improve accuracy of myasthenia gravis evaluations
https://www.mdedge.com/neurology/article/211179/neuromuscular-disorders/achr-autoantibody-subtype-testing-may-improve?channel=53
Jake Remaly

Oct 29th, 2019 - AUSTIN, TEX. – When testing for acetylcholine receptor (AChR) autoantibodies in patients with suspected myasthenia gravis, testing for binding antibodies and for modulating antibodies is more accurate than testing for either subtype alone, researc.

Which patients are most likely to have a positive RNS test for myasthenia gravis?
https://www.mdedge.com/jcomjournal/article/210392/neuromuscular-disorders/which-patients-are-most-likely-have-positive-rns?channel=39313
Erik Greb

Oct 18th, 2019 - AUSTIN, TEX. – Patients with suspected myasthenia gravis are more likely to have positive repetitive nerve stimulation (RNS) findings if they undergo testing in an inpatient setting, are seropositive, or are classified as Myasthenia Gravis Foundat.

Neurologists consider flu shot safe in most patients with autoimmune neuromuscular disorders
https://www.mdedge.com/jcomjournal/article/210352/neuromuscular-disorders/neurologists-consider-flu-shot-safe-most-patients?channel=39313
Erik Greb

Oct 17th, 2019 - AUSTIN, TEX. – Neurologists consider influenza vaccination to be safe in most patients with autoimmune neuromuscular disorders such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), according to a survey presented.

Placebo response in negative rituximab BeatMG trial provides important lessons
https://www.mdedge.com/clinicalneurologynews/article/210310/neuromuscular-disorders/placebo-response-negative-rituximab/page/0/1?channel=39313

Oct 17th, 2019 - Suggestions from the data The post hoc subgroup analysis should be interpreted with caution, and the study does not provide firm conclusions, Dr. Nowak noted.

see more →

Patient Education  21 results see all →